Clover (ASX:CLV) Change In Receivables : A$0.00 Mil (TTM As of Jan. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Clover Change In Receivables?

Clover's change in receivables for the quarter that ended in Jan. 2024 was A$0.00 Mil. It means Clover's Accounts Receivable stayed the same from Jul. 2023 to Jan. 2024 .

Clover's change in receivables for the fiscal year that ended in Jul. 2023 was A$0.00 Mil. It means Clover's Accounts Receivable stayed the same from Jul. 2022 to Jul. 2023 .

Clover's Accounts Receivable for the quarter that ended in Jan. 2024 was A$13.08 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Clover's Days Sales Outstanding for the six months ended in Jan. 2024 was 87.39.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Clover's liquidation value for the six months ended in Jan. 2024 was A$15.31 Mil.

Clover Change In Receivables Historical Data

The historical data trend for Clover's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Change In Receivables Chart

Clover Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Change In Receivables

Get a 7-Day Free Trial

Clover Semi-Annual Data
	Jul14	Jan15	Jul15	Jan16	Jul16	Jan17	Jul17	Jan18	Jul18	Jan19	Jul19	Jan20	Jul20	Jan21	Jul21	Jan22	Jul22	Jan23	Jul23	Jan24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Clover Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jan. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Clover (ASX:CLV) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Clover's Days Sales Outstanding for the quarter that ended in Jan. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	13.082	/	27.321	*	91
=	87.39

2. In Ben Graham's calculation of liquidation value, Clover's accounts receivable are only considered to be worth 75% of book value:

Clover's liquidation value for the quarter that ended in Jan. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.052	-	19.564	+	0.75 * 13.082	+	0.5 * 34.014
=	15.31

Clover Change In Receivables Related Terms

Thank you for viewing the detailed overview of Clover's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Clover (ASX:CLV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Clover Corp Ltd (ASX:CLV) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

39 Pinnacle Road, Altona North, Melbourne, VIC, AUS, 3025

Website

https://www.clovercorp.com.au

Clover Corp Ltd provides nutritional and functional ingredients. The company is involved in the production of encapsulated powders, and research and product development of functional food and infant nutrition ingredients. It offers Nu-Mega Hi docosahexaenoic acid tuna oils for use in infant formula and pharmaceutical products; and Ocean Gold refined tuna oils. Its products include DHA oils, DHA powders, and Microencapsulation. Geographically, the group has a business presence in Australia, New Zealand, Asia, Europe, and the Americas. Majority of the revenue is derived from Asia.